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Abstract
Background: Apigenin is a plant-derived flavonoid with antioxidative and antiapoptotic
effects. Bone marrow stromal cells (BMSCs) are a type of mesenchymal stem cells
(MSCs) that may recover damaged ovaries. It seems that apigenin may promote the
differentiation of MSCs.
Objective: The aim of this study was to investigate the effect of coadministration of
apigenin and BMSCs on the function, structure, and apoptosis of the damaged ovaries
after creating a chemotherapy model with cyclophosphamide in rat.
Materials and Methods: For chemotherapy induction and ovary destruction,
cyclophosphamide was injected intraperitoneally to 40 female Wistar rats (weighing
180–200 gr, 10 wk old) for 14 days. Then, the rats were randomly divided into four
groups (n = 10/each): control, apigenin, BMSCs and coadministration of apigenin
and BMSCs. Injection of apigenin was performed intraperitoneally and BMSC
transplantation was performed locally in the ovaries. The level of anti-mullerian
hormone serum by ELISA kit, the number of oocytes by superovulation, the number
of ovarian follicles in different stages by H&E staining, and the expression of ovarian
Bcl-2 and Bax proteins by western blot were assessed after four wk.
Results: The results of serum anti-mullerian hormone level, number of oocytes and
follicles, and Bcl-2/Bax expression ratio showed that coadministration of apigenin and
BMSCs significantly recovered the ovarian function, structure, and apoptosis compared
to the control, BMSC, and apigenin groups (p < 0.001).
Conclusion: The results suggest that the effect of coadministration of apigenin and
BMSCs is maybe more effective than the effect of their administrations individually on
the recovery of damaged ovaries following the chemotherapy with cyclophosphamide
in rats.
Key words: Apigenin, Bone marrow stromal cells, Chemotherapy, Ovary,
Regeneration.
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1. Introduction
Ovary is one of the most susceptible organs
against chemotherapy in young girls and
women who fight cancer (1). Side effects of
chemotherapy can damage ovarian granulosa
cells so that folliculogenesis may be impaired
(2). Cyclophosphamide is one of the most widely
used chemotherapy drugs which causes damage
to the ovaries (3). There are several treatment
procedures for damaged ovaries such as hormone
therapy, ovarian tissue freezing, stem cell therapy,
and the use of antioxidants (4). Certainly, hormone
therapy is not suitable for cancer patients because
it increases the likelihood of cancer recurrence
(5). Ovarian tissue freezing is also unfavorable
because it requires two surgeries to remove and
transfer tissue and the possibility of returning
its performance is low (6). Lately, it has been
noticed that transplantation of bone marrow
stromal cells (BMSCs), a type of mesenchymal
stem cells (MSCs), may recover ovarian impair
after chemotherapy (7). BMSCs can secrete many
growth factors, differentiate into other cell lines,
and replace defective cells (8). On the other hand,
it has been shown that the use of apigenin as an
antioxidant may preserve the damaged ovaries
(9). Apigenin is from flavonoids category that
is present in some fruits and vegetables with
antioxidative, antiapoptotic, and anti-inflammatory
properties (10). Apigenin prevents cell apoptosis
by suppressing reactive oxygen species (ROS)
compounds (11). Moreover, apigenin may promote
the differentiation of stem cells (12, 13).
Although the useful impacts of apigenin and
BMSCs on damaged ovaries have been studied
individually, there is no report yet about the impact
of coadministration of them on the improvement
of damaged ovaries following chemotherapy.
Thus, for the first time, we assessed the impact
of coadministration of apigenin and BMSCs
on ovarian function, structure, and apoptosis
after creating a model of chemotherapy with
cyclophosphamide in rat.
2. Materials and Methods
2.1. Experimental animals
In this experimental study, 40 adult female
Wistar rats (weighing 180–200 gr, 10 wk old)
were applied. The rats were kept at a controlled
temperature (25±2°C) and had free access to
water and food. Vaginal smear samples were
obtained daily and only those displayed at least
two consecutive normal vaginal estrus cycles were
applied in the tests.
2.2. Culture and characterization of
BMSCs
Immediately after killing an adult rat, femurs
and tibias were taken out. To kill the rat, it was
first anesthetized with an intraperitoneal injection
of 80 mg/kg ketamine and 10 mg/kg xylazine
and then cervical dislocation was performed. The
bone marrow was flushed out with 10 ml of
Dulbecco’s Modified Eagle Medium (DMEM) + 10%
fetal bovine serum (FBS) (Gibco, Germany) in
two flasks and incubated in the culture medium
containing 10% FBS and 1% penicillin/streptomycin
(Gibco, Germany), at 37°C, 95% humidity, and 5%
CO2. After 48 hr, the culture medium was replaced.
The adherent cells were subcultured four times (14,
15). To analyze the expression of the BMSC surface
markers, more than 100,000 cells were incubated
to fluorescence-labeled monoclonal antibodies
against CD29, CD34, CD44, CD45, and CD90
(Sigma, China). After a 10-min wash with PBS, the
labeled cells were analyzed using a flow cytometry
apparatus (BD FACS Calibur) (7).
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2.3. Creating the chemotherapymodel
To damage the ovaries, a chemotherapy model
was performed. First, cyclophosphamide (Sigma,
China) diluted in normal saline was injected at 50
mg/kg intraperitoneally, then injected at 8 mg/kg
daily for 13 consecutive days, in total for 14 days.
The percentage of cyclophosphamide dilution was
1% (16).
2.4. Grouping and injection methods
in the groups
After creating the model of chemotherapy, the
rats were randomly divided into four groups (n =
10/each): (I) Control group, 25 µl of culture medium
(DMEM) was directly injected into the bilateral
ovaries once; (II) BMSC group, 2 × 106 BMSCs
suspended in 25 µl of DMEMwere directly injected
into the bilateral ovaries once (17); (III) Apigenin
group, 10 mg/kg of apigenin (diluted in DMSO) was
injected intraperitoneally for 14 days (18); and (IV)
Co-administration of apigenin and BMSC group,
injection of apigenin and BMSC were performed
together. To inject BMSCs into the bilateral ovaries,
the rats were anesthetized and a longitudinal
incision about 2 cm was performed below the
costovertebral angle on the dorsal midline of the
rats to expose the bilateral ovaries. Then, BMSCs
or culture medium (DMEM) was injected into the




Four wk after treatment, serum anti-mullerian
hormone (AMH) level of the groups was measured
by enzyme-linked immunosorbent assay (ELISA) kit
(Shanghai Crystal day Biotech, China) in all groups,
according to the manufacturer’s instruction (20).
2.6. Evaluating the ability of ovulation
Four wk after treatment, the rats were
intraperitoneally superovulated by 150 IU/kg
of pregnant mare serum gonadotropin (PMSG)
(Sigma, China), followed by 75 IU/kg of human
chorionic gonadotropin (hCG) (Sigma, China) 48
hr later; about 14–16 hr after the hCG injection,
oocytes were collected from the oviduct (7, 21).
2.7. Histological evaluation
Four wk after treatment, harvested ovaries
were fixed in 4% paraformaldehyde. After paraffin
embedding, serial sections at 5-µm thickness
were prepared. From each ovary, five sections
were randomly selected and routine hematoxylin
and eosin (H&E) staining was accomplished for
histological evaluation with light microscopy. The
number of follicles in different stages comprising
primordial, primary, secondary, and antral was
counted (22, 23).
2.8. Western blot assays
“Four wk after treatment, the ovaries were
lysed with RIPA buffer (Cell Signaling Technology,
Netherlands) and protease inhibitor (Roche,
Switzerland) on ice for 30 min. The mixture was
centrifuged for 20 min at 4°C. Then, identical
values of proteins (80 µg) were loaded on
sodium dodecyl sulfate (SDS) polyacrylamide
gel and detached by electrophoresis. After
transferring the proteins to nitrocellulose
membranes (Amersham Biosciences, USA), the
membranes were blocked by 5% skim milk in
Tris-buffered saline (TBS) and incubated with
primary antibodies for Bax (1:1000), Bcl-2 (1:1000)
and 𝛽-actin (1:1000) (Abcam, USA) overnight at
4°C. After washing with TBS, 0.1% Tween 20
(TBS-T), the membranes were incubated with
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secondary antibody conjugated with horseradish
peroxidase (HRP). Immunoreactive bands were
observed with a chemiluminescence detection
system (Amersham Biosciences, USA). Densities
of the bands were quantified by densitometric
analysis and Image J software. 𝛽-actin was used as
the internal control to normalize the protein levels”
(24).
2.9. Ethical consideration
All procedures were approved by ethical
committee of Semnan University of Medical
Sciences (Semnan, Iran) and Islamic Azad
University (Tehran, Iran). The ethical code is
IR.IAU.SRB.REC.1397.136.
2.10. Statistical analysis
After verifying the normality of variances
assumptions, data were analyzed using the
Statistical Package for Social Sciences (SPSS),
version 16/0 (SPSS Inc., Chicago, Illinois, USA)
and one-way analysis of variance (ANOVA) and
Tukey statistical tests. Mean ± standard error (SE)
difference was considered significant at p < 0.05
level.
3. Results
3.1. BMSC cultivation and
characterization
A few days later, the cultured BMSCs were
spindle-shaped. After repeating passages, the
BMSCs became morphologically homogeneous.
Most of the BMSCs expressed stromal cell markers
including CD29, CD44, and CD90 while did
not express the markers of hematopoietic cells
comprising CD34 and CD45 (Figure 1).
3.2. Level of AMH serum
Four weeks after the treatment, the results of
the ELISA test demonstrated that the levels of AMH
serum in the BMSC group (p = 0.001) and apigenin
group (p = 0.02) were significantly higher compared
to the control group. Moreover, the results of the
coadministration group were significantly higher
in comparison with BMSC, apigenin and control
groups (p < 0.001) (Figure 2).
3.3. Evaluating the ability of ovulation
The results of ovulation ability showed that the
number of collected oocytes after superovulation
in BMSC group (p < 0.001) and apigenin group
(p = 0.001) was significantly more than the control
group and the results of co-administration group
were significantly more than BMSC, apigenin and
control groups (p < 0.001; Figure 3).
3.4. Histological evaluation of the
ovaries
The results of H&E staining showed that the
number of ovarian follicles in different stages in
BMSC group (p = 0.002) and apigenin group (p
= 0.019) was significantly higher than the control
group. The number of follicles in coadministration
groupwas significantly higher than BMSC, apigenin
and control groups (p < 0.001, Figure 4).
3.5. Analysis of the Bcl-2 and Bax
expression in the ovaries
The results of expression of ovarian Bcl-2
and Bax proteins showed that Bcl-2 expression
in the experimental groups was significantly
higher than the control group (p < 0.001), and
in coadministration group, it was significantly
Page 554 https://doi.org/10.18502/ijrm.v13i7.7372
International Journal of Reproductive BioMedicine Impact of apigenin and BMSCs on rat damaged ovaries
higher than the BMSC and apigenin groups (p
< 0.001). Bax expression in the experimental
groups was significantly lower than the control
group (p < 0.001), and in coadministration
group, it was significantly lower than the BMSC
and apigenin groups (p < 0.001). The Bcl-
2/Bax ratio was significantly increased in the
coadministration group in comparison with the
control, BMSC, and apigenin groups (p < 0.001,
Figure 5).
Figure 1. Cultivation and identification of bone marrow stromal cells (BMSCs). (A) Cultured BMSCs at passage 4. (B) The results of
flow cytometry show BMSCs are positive for CD29, CD44, and CD90 and negative for CD34 and CD45. Scale bar: 50 µm.
Figure 2. The level of AMH serum in the control and experimental groups four weeks after treatment. *P < 0.05, **P < 0.01, ***P
< 0.001 versus control group.
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Figure 3. The oocytes were collected from the ovaries following superovulation four weeks after treatment in (A) Control group,
(B) BMSC group, (C) Apigenin group, (D) Coadministration of the BMSC and apigenin groups, and (E) The results of the number
of oocytes. Scale bars: 100 µm. **P < 0.01, ***P < 0.001 versus control group.
Figure 4. The number of follicles four weeks after treatment. Hematoxylin and eosin (H&E) staining of ovaries in (A) Control group,
(B) BMSC group, (C) Apigenin group, (D) Coadministration of the BMSC and apigenin groups, and (E) The results of the number
of follicles in different stages. Scale bars: 100 µm. *P < 0.05, **P < 0.01, ***P < 0.001 versus control group.
Figure 5. The expression of Bcl-2 and Bax proteins by western blot assay four weeks after treatment. (A) The results of the
expression of ovarian Bcl-2 protein. (B) The results of the expression of ovarian Bax protein. (C) The results of the Bcl-2/Bax ratio.
(D) Immunoblot of Bcl-2, Bax and 𝛽-actin proteins. **P < 0.01, ***P < 0.001 versus control group.
Page 556 https://doi.org/10.18502/ijrm.v13i7.7372
International Journal of Reproductive BioMedicine Impact of apigenin and BMSCs on rat damaged ovaries
4. Discussion
In the current study, for the first time, we
investigated the impact of coadministration
of apigenin and BMSCs on damaged ovaries
after creating a model of chemotherapy with
cyclophosphamide in rats. Overall, the results
showed that a coadministration of apigenin
and BMSC significantly improved the function,
structure, and apoptosis in the damaged ovaries.
We examined the ovaries in terms of function,
structure, and apoptosis. To assess ovarian
function, the ability of ovulation by superovulation
and the level of AMH serum by ELISA kit were
evaluated. AMH is a dimeric glycoprotein from
transforming growth factor 𝛽 family which is
produced by granulosa cells of preantral follicles.
Therefore, when apoptosis occurs in granulosa
cells, the amount of AMH decreases. Indeed,
AMH is an important indicator for the ovarian
follicular content and can be used as a marker
for ovarian dysfunction (25). To assess ovarian
structure, the number of follicles in different
stages were evaluated by H&E staining. Also
to assess apoptosis in ovarian granulosa cells,
the expression ratio of Bcl-2/Bax proteins was
evaluated by western blot because the Bcl-2
and Bax genes are respectively characterized as
antiapoptotic and proapoptotic agents (24, 26).
The results of the BMSC group were significantly
more desirable than the control group that these
results were consistent with other studies (7, 27).
BMSCs as a type of MSCs are a suitable candidate
for cell therapy in damaged ovaries. Liu and co-
workers have reported that MSCs improve tissues
chiefly via differentiation and paracrine effects (28).
Various studies have demonstrated that BMSCs
secrete some growth factors which can recover
damaged ovaries and prevent cell apoptosis. Some
of these growth factors are insulin-like growth
factor 1, vascular endothelial growth factor, basic
fibroblast growth factor, and hepatocyte growth
factor (7, 27).
On the other hand, the results of apigenin
group showed that apigenin as an antioxidant
significantly improved the ovaries than the control
group. These results consent with Tang’s study.
Tang and co-workers showed that apigenin could
protect ovaries by inhibiting the self-renewal
capacity of human ovarian cancer (9). While the
results of our study were contrary to Soyman’s
study, Soyman and co-workers showed that
a single dose of 15 mg/kg apigenin has no
significant protective effect on ovarian injury
following ischemia and reperfusion (29). The
reason for this contradiction was probably due to
the use of a single dose of apigenin in Soyman’s
study against the administration of 10 mg/kg
apigenin for 14 consecutive days in our study.
Some articles have reported that apigenin has
protective effects on various cell types. Anusha and
co-workers showed that apigenin has protective
effects on the rat model of Parkinson’s disease
by suppressing neuro-inflammation factors and
inhibiting apoptosis induced by oxidative stress
(18). Zhang and co-workers showed that apigenin
has neuroprotective effects on spinal cord injury in
rats (30). Liu and co-workers showed that apigenin
has a protective role in undifferentiated dental pulp
cells (31). Apigenin plays an important role in fatty
acid transport and lipid catabolism in mitochondria.
Apigenin increases mitochondrial activity and
produces ATP by increasing 𝛽-oxidation of fatty
acids hence providing energy for cellular growth
suppressing apoptosis (32). In addition, apigenin
can prevent cell apoptosis by repressing ROS
compounds (11). Accumulation of ROS in ovarian
follicles leads to discharge in the ATP repository,
which reduces follicle quality. Antioxidants as ROS
scavengers and energy production facilitators may
be responsible for beneficial effects on ovarian
function and follicular survival (33).
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Given the potential effects of apigenin on the
differentiation of stem cells, coadministration of
apigenin and BMSCs may offer a novel clinical
approach to the recovery of damaged ovaries
following chemotherapy. The results of the
coadministration group were significantly more
desirable than BMSC, apigenin, and control
groups. The reasons were likely related to the
compound of beneficial effects of MSCs and
apigenin with various action mechanisms in
the recovery of ovaries after chemotherapy.
Additionally, apigenin might increase the
differentiation of the transplanted BMSCs to
replace damaged ovarian cells. Dawn and co-
workers reported that the differentiation of adult
bone marrow-derived cells into other cells of
various organs has been repeatedly confirmed
(8). Samet and coworkers have reported that
apigenin has the potential synergistic effects
on the differentiation of hematopoietic stem
cells (13). Zhang and co-workers have shown
that apigenin is effective on differentiating
MSCs in vitro (12). They have reported that
apigenin promotes the osteogenesis of hMSCs
by increasing alkaline phosphatase activity
and mineralization in hMSCs. Thereby using
apigenin and MSCs in the ovary might cause
osteogenic differentiation inside the ovaries.
In this regard, Mao and co-workers have
reported that the two main factors for osteogenic
differentiation from MSCs are substrate stiffness
and neighboring cells (34). Therefore, due to
the lack of substrate stiffness and osteocyte in
ovaries, the probability of BMSC differentiation
into osteogenic cells was low. Zhang and co-
workers in an in vitro study have shown that
apigenin inhibits inflammatory factors and at
doses < 40 µmol/L have no harmful effect on
MSCs. However, at the dose of 80 µmol/L,
apigenin significantly increased apoptosis in
these cells (35). This issue shows that apigenin
as an antioxidant may be harmful if consumed
in too large quantities. In the present study, we
observed that 10 mg/kg apigenin with BMSC
transplantation has favorable effects on the rat
ovarian restoration.
In the current study, BMSC transplantation
was performed locally in the ovaries while
apigenin injection was given intraperitoneally.
According to related studies, our hypothesis was
that the prescribed models would probably be
the most effective mode. Liu and co-workers after
comparing the local and systemic administration
of MSCs reported that local administration of
stem cells is the most efficient way for stem
cell homing and differentiation (28). Also, the
effectiveness of intraperitoneal injection of
apigenin in other tissues has been repeatedly
reported (18, 30, 31). While the local injection
of apigenin in the ovary has not been done so
far.
4.1. Limitation
This study had some limitations. The number
of samples was small, so the larger sample size
is required. Also, more research is necessary
to clarify the molecular mechanisms underlying
apigenin and BMSCs function in ovarian repair after
chemotherapy. In addition, the effect of different
doses of apigenin and the fate of transplanted
BMSCs have not been investigated in this study.
5. Conclusion
The results suggest that the effect of co-
administration of apigenin and BMSCs is
maybe more effective than the effect of their
administrations individually on the recovery of
damaged ovaries following the chemotherapy with
cyclophosphamide in rats.
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